AI Verdict
VRTX has stronger fundamentals based on our AI analysis.
VRTX vs ZTS Fundamental Comparison
| Metric | VRTX | ZTS |
|---|---|---|
| Revenue | $12.0B | $9.5B |
| Net Income | $4.0B | $2.7B |
| Net Margin | 32.9% | 28.2% |
| ROE | 21.2% | 80.2% |
| ROA | 15.4% | 17.3% |
| Current Ratio | 2.90x | 3.03x |
| Debt/Equity | 0.01x | 2.71x |
| EPS | $15.32 | $6.02 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
VRTX vs ZTS: Frequently Asked Questions
Is VRTX or ZTS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), VRTX has stronger fundamentals. VRTX is rated BUY (86% confidence) while ZTS is rated BUY (78% confidence). This is not investment advice.
How does VRTX compare to ZTS fundamentally?
VERTEX PHARMACEUTICALS INC / MA has ROE of 21.2% vs Zoetis Inc.'s 80.2%. Net margins are 32.9% vs 28.2% respectively.
Which stock pays higher dividends, VRTX or ZTS?
VRTX has a dividend yield of N/A or no dividend while ZTS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in VRTX or ZTS for long term?
For long-term investing, consider that VRTX has BUY rating with 86% confidence, while ZTS has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about VRTX vs ZTS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For VRTX vs ZTS, the AI consensus favors VRTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.